Effects of angiotensin Ⅱ receptor antagonist on expression of plasminogen activator inhibitor-1 in the renal biopsy of patients with chronic kidney disease
10.3760/cma.j.issn.1673-4904.2010.16.004
- VernacularTitle:血管紧张素Ⅱ受体拮抗剂对慢性肾脏病患者肾组织中纤溶酶原激活物抑制物-1表达的影响
- Author:
Wenge WANG
;
Xia LI
- Publication Type:Journal Article
- Keywords:
Plasminogen activator inhibitor 1;
Endothelial cells;
Vahartan;
Chronic kidney disease
- From:
Chinese Journal of Postgraduates of Medicine
2010;33(16):12-14
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of angiotensin Ⅱreceptor antagonist (ARB) on expression of plasminogen activator inhibitor(PAI)-1 in the human renal biopsy of patients with chronic kidney disease(CKD)and analyse its clinical significance.Methods PAI-1 expression of 63 specimens with CKD was detected by immunohistochemistry and quantitative analysis was achieved by image analysis system. meanwhile, the patients'clinical data were collected,and PAI-1 expression of 63 specimens with CKD was compared with that of normal renal tissue(19 cases).Results Compared with the normal renal tissue,the expression of PAI-1 in CKD 1,2 and 3 stage wag respectively drastically increased(P<0.05).The expression of PAI-1 in CKD 3 stage was higher than that in CKD 1 and 2 stage(P<0.05).The expression of PAI-1 in the patients treated by valsartan[renal corpuscle(4.73±1.18)%,renal tubule(37.16±6.81)%]was lower than that with no treatment[renal corpuscle(5.81±1.95)%,renal tubule(43.22 ±10.25)%](P<0.05).Conclusions It suggests that the abnormal expression of PAI-1 in CKD play an important role in the progression of glomerular and tubulointerstitiai sclerosis in patients with CKD.ARB may prevent the development of renal inflammation and sclerosis by inhibiting the production of PAI-1.ARB may contribute to the prevention and therapy of CKD.
